Moreover, inhibition therapy targeting EZH2 in both models alleviated peritoneal fibrosis and suppressed the activation of various pro-fibrotic signaling pathways, such as TGF-β1/Smad3, Notch1, EGFR, and Src, as well as phosphorylation events involving STAT3 and NF-κB. The gene discussed is EZH2; the disease is Peritoneal Fibrosis.